Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class

AMG 133 For Obesity Is One To Watch In CV Portfolio

 
• By Mandy Jackson

The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December. 

Human heart with blood vessels
About 20% of people have elevated Lp(a) levels that increase their cardiovascular disease risk • Source: Shutterstock

More from Clinical Trials

More from R&D